Clinical Trial Supplies Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Clinical Phase (Phase I, Phase II, Phase III, Others), By Product & Services (Manufacturing, Storage & Distribution, Supply Chain Management), By Therapeutic Use (Oncology, CNS Diseases, Cardiovascular Diseases, Infectious Disease, Metabolic Disorders, Others), By End User (Pharmaceutical, Biologics, Medical device, Others), By Region & Competition, 2021-2031F

January 2026 | 185 pages | ID: C58CC9A84B37EN
TechSci Research

Abstracts

The Global Clinical Trial Supplies Market is projected to expand from USD 3.18 Billion in 2025 to USD 4.98 Billion by 2031, registering a CAGR of 7.76%. This sector encompasses a wide array of necessities, including investigational medicinal products, medical devices, and ancillary items like testing kits and packaging essential for compliant studies. Growth is largely fueled by the escalating number of clinical trials globally and rising research and development investments within the biopharmaceutical industry. Furthermore, the increasing emphasis on biologics and orphan drugs requires specialized handling and logistics, thereby boosting the demand for secure and resilient supply chain solutions.

However, the market encounters substantial obstacles related to complex cold chain management, especially for temperature-sensitive biologics that require rigorous environmental controls during transit. Varying regulations across different regions also introduce compliance difficulties that can delay supply schedules and raise operational expenses. Highlighting the scale of investment requiring this infrastructure, the 'European Federation of Pharmaceutical Industries and Associations' reported in '2024' that 'the research-based pharmaceutical industry invested an estimated 55,000 million euros in research and development in Europe', confirming the vital need for efficient supply chain mechanisms to sustain such significant financial commitments.

Market Driver

Rising pharmaceutical and biopharmaceutical R&D spending acts as a major engine for the Global Clinical Trial Supplies Market. As companies strive to discover new treatments for chronic and rare conditions, their financial outlays necessitate a corresponding increase in acquiring investigational products and ancillary supplies. This heightened investment drives the demand for precise supply chain logistics to handle material distribution across global sites. For instance, according to Roche, January 2025, in the 'Finance Report 2024', the company's research and development expenditure hit 'CHF 13.0 billion', illustrating the massive capital directed toward therapeutic advancement that requires extensive clinical supply backing.

Concurrently, the market is propelled by the growing volume of registered clinical trials worldwide, which significantly broadens the operational landscape for vendors. This increase, especially with complex biologics, calls for strong infrastructure to guarantee product quality and timely delivery across varied locations. According to the National Institutes of Health, April 2025, in the article 'ClinicalTrials.gov: A 25-Year Journey to a Half-Million Registered Studies', the registry recorded its '500,000th' clinical study in 2024, emphasizing the vast scale of research needing supply management. To meet these rising needs, according to Cencora, November 2025, in the 'Cencora Announces $1 Billion Investment' press release, the firm intends to invest '$1 billion' through 2030 to strengthen its pharmaceutical distribution network.

Market Challenge

The intricacies of cold chain management present a significant hurdle to the advancement of the global clinical trial supplies market. With the industry pivoting toward biologics and orphan drugs, the necessity for stringent environmental controls results in a delicate logistical framework. These temperature-sensitive items require continuous refrigeration or freezing from production through to administration; any temperature deviation during transport can spoil investigational products, causing major financial setbacks and study delays. This susceptibility compels companies to incur high expenses for specialized packaging and monitoring, straining budgets and limiting efficient market scalability in regions with developing infrastructure.

This logistical pressure is further amplified by the sheer volume of sensitive therapies currently in the pipeline. According to the 'Pharmaceutical Research and Manufacturers of America', in '2024', 'there were more than 8,000 medicines in clinical development' worldwide, a large portion of which are biologics requiring strict temperature maintenance. Managing the shipment of such a vast quantity of sensitive products heightens the risk of waste. Consequently, the elevated likelihood of supply chain failures in complex environments restricts the reach of clinical trials into new regions, thereby curbing the overall growth potential of the supplies market.

Market Trends

The move toward Decentralized Clinical Trial (DCT) supply logistics is reshaping the market by shifting care from standard investigator sites to patients' homes. This approach requires flexible supply chains that can handle direct-to-patient deliveries while strictly upholding temperature controls and chain of custody. To support this dispersed model, logistics providers are creating hyper-local distribution centers that ensure protocol compliance outside of traditional clinical environments. Confirming this shift, according to DHL Group, April 2025, in the 'DHL Group to Invest EUR 2 Billion by 2030 in DHL Health Logistics' press release, the firm has pledged '?2 billion' to bolster its life sciences logistics, specifically aiming to meet demand for specialized services in complex trial designs.

At the same time, the integration of Artificial Intelligence for Demand Forecasting is refining inventory management via predictive analytics. By analyzing data such as enrollment speeds and usage patterns, AI algorithms can accurately anticipate supply requirements, thereby minimizing drug waste and preventing shortages. This capability enables sponsors to adapt distribution strategies in real-time, ensuring materials are on hand exactly when required. Illustrating this development, according to Thermo Fisher Scientific, October 2025, in the 'Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI' press release, the company has incorporated artificial intelligence throughout its PPD clinical research division to 'improve the cycle time' of trials and speed up drug development.

Key Market Players

• Thermo Fisher Scientific Inc.
• Almac Group
• Novo Holdings A/S
• Marken LLP
• PCI Pharma Services
• Sharp Services LLC
• Cencora, Inc.
• Myonex LLC
• Parexel International Corporation
• ICON Plc

Report Scope

In this report, the Global Clinical Trial Supplies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Clinical Trial Supplies Market, By Clinical Phase
• Phase I
• Phase II
• Phase III
• Others
• Clinical Trial Supplies Market, By Product & Services
• Manufacturing
• Storage & Distribution
• Supply Chain Management
• Clinical Trial Supplies Market, By Therapeutic Use
• Oncology
• CNS Diseases
• Cardiovascular Diseases
• Infectious Disease
• Metabolic Disorders
• Others
• Clinical Trial Supplies Market, By End User
• Pharmaceutical
• Biologics
• Medical device
• Others
• Clinical Trial Supplies Market, By Region
• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trial Supplies Market.

Available Customizations:

Global Clinical Trial Supplies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

1.1. Market Definition
1.2. Scope of the Market
  1.2.1. Markets Covered
  1.2.2. Years Considered for Study
  1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMER

5. GLOBAL CLINICAL TRIAL SUPPLIES MARKET OUTLOOK

5.1. Market Size & Forecast
  5.1.1. By Value
5.2. Market Share & Forecast
  5.2.1. By Clinical Phase (Phase I, Phase II, Phase III, Others)
  5.2.2. By Product & Services (Manufacturing, Storage & Distribution, Supply Chain Management)
  5.2.3. By Therapeutic Use (Oncology, CNS Diseases, Cardiovascular Diseases, Infectious Disease, Metabolic Disorders, Others)
  5.2.4. By End User (Pharmaceutical, Biologics, Medical device, Others)
  5.2.5. By Region
  5.2.6. By Company (2025)
5.3. Market Map

6. NORTH AMERICA CLINICAL TRIAL SUPPLIES MARKET OUTLOOK

6.1. Market Size & Forecast
  6.1.1. By Value
6.2. Market Share & Forecast
  6.2.1. By Clinical Phase
  6.2.2. By Product & Services
  6.2.3. By Therapeutic Use
  6.2.4. By End User
  6.2.5. By Country
6.3. North America: Country Analysis
  6.3.1. United States Clinical Trial Supplies Market Outlook
    6.3.1.1. Market Size & Forecast
      6.3.1.1.1. By Value
    6.3.1.2. Market Share & Forecast
      6.3.1.2.1. By Clinical Phase
      6.3.1.2.2. By Product & Services
      6.3.1.2.3. By Therapeutic Use
      6.3.1.2.4. By End User
  6.3.2. Canada Clinical Trial Supplies Market Outlook
    6.3.2.1. Market Size & Forecast
      6.3.2.1.1. By Value
    6.3.2.2. Market Share & Forecast
      6.3.2.2.1. By Clinical Phase
      6.3.2.2.2. By Product & Services
      6.3.2.2.3. By Therapeutic Use
      6.3.2.2.4. By End User
  6.3.3. Mexico Clinical Trial Supplies Market Outlook
    6.3.3.1. Market Size & Forecast
      6.3.3.1.1. By Value
    6.3.3.2. Market Share & Forecast
      6.3.3.2.1. By Clinical Phase
      6.3.3.2.2. By Product & Services
      6.3.3.2.3. By Therapeutic Use
      6.3.3.2.4. By End User

7. EUROPE CLINICAL TRIAL SUPPLIES MARKET OUTLOOK

7.1. Market Size & Forecast
  7.1.1. By Value
7.2. Market Share & Forecast
  7.2.1. By Clinical Phase
  7.2.2. By Product & Services
  7.2.3. By Therapeutic Use
  7.2.4. By End User
  7.2.5. By Country
7.3. Europe: Country Analysis
  7.3.1. Germany Clinical Trial Supplies Market Outlook
    7.3.1.1. Market Size & Forecast
      7.3.1.1.1. By Value
    7.3.1.2. Market Share & Forecast
      7.3.1.2.1. By Clinical Phase
      7.3.1.2.2. By Product & Services
      7.3.1.2.3. By Therapeutic Use
      7.3.1.2.4. By End User
  7.3.2. France Clinical Trial Supplies Market Outlook
    7.3.2.1. Market Size & Forecast
      7.3.2.1.1. By Value
    7.3.2.2. Market Share & Forecast
      7.3.2.2.1. By Clinical Phase
      7.3.2.2.2. By Product & Services
      7.3.2.2.3. By Therapeutic Use
      7.3.2.2.4. By End User
  7.3.3. United Kingdom Clinical Trial Supplies Market Outlook
    7.3.3.1. Market Size & Forecast
      7.3.3.1.1. By Value
    7.3.3.2. Market Share & Forecast
      7.3.3.2.1. By Clinical Phase
      7.3.3.2.2. By Product & Services
      7.3.3.2.3. By Therapeutic Use
      7.3.3.2.4. By End User
  7.3.4. Italy Clinical Trial Supplies Market Outlook
    7.3.4.1. Market Size & Forecast
      7.3.4.1.1. By Value
    7.3.4.2. Market Share & Forecast
      7.3.4.2.1. By Clinical Phase
      7.3.4.2.2. By Product & Services
      7.3.4.2.3. By Therapeutic Use
      7.3.4.2.4. By End User
  7.3.5. Spain Clinical Trial Supplies Market Outlook
    7.3.5.1. Market Size & Forecast
      7.3.5.1.1. By Value
    7.3.5.2. Market Share & Forecast
      7.3.5.2.1. By Clinical Phase
      7.3.5.2.2. By Product & Services
      7.3.5.2.3. By Therapeutic Use
      7.3.5.2.4. By End User

8. ASIA PACIFIC CLINICAL TRIAL SUPPLIES MARKET OUTLOOK

8.1. Market Size & Forecast
  8.1.1. By Value
8.2. Market Share & Forecast
  8.2.1. By Clinical Phase
  8.2.2. By Product & Services
  8.2.3. By Therapeutic Use
  8.2.4. By End User
  8.2.5. By Country
8.3. Asia Pacific: Country Analysis
  8.3.1. China Clinical Trial Supplies Market Outlook
    8.3.1.1. Market Size & Forecast
      8.3.1.1.1. By Value
    8.3.1.2. Market Share & Forecast
      8.3.1.2.1. By Clinical Phase
      8.3.1.2.2. By Product & Services
      8.3.1.2.3. By Therapeutic Use
      8.3.1.2.4. By End User
  8.3.2. India Clinical Trial Supplies Market Outlook
    8.3.2.1. Market Size & Forecast
      8.3.2.1.1. By Value
    8.3.2.2. Market Share & Forecast
      8.3.2.2.1. By Clinical Phase
      8.3.2.2.2. By Product & Services
      8.3.2.2.3. By Therapeutic Use
      8.3.2.2.4. By End User
  8.3.3. Japan Clinical Trial Supplies Market Outlook
    8.3.3.1. Market Size & Forecast
      8.3.3.1.1. By Value
    8.3.3.2. Market Share & Forecast
      8.3.3.2.1. By Clinical Phase
      8.3.3.2.2. By Product & Services
      8.3.3.2.3. By Therapeutic Use
      8.3.3.2.4. By End User
  8.3.4. South Korea Clinical Trial Supplies Market Outlook
    8.3.4.1. Market Size & Forecast
      8.3.4.1.1. By Value
    8.3.4.2. Market Share & Forecast
      8.3.4.2.1. By Clinical Phase
      8.3.4.2.2. By Product & Services
      8.3.4.2.3. By Therapeutic Use
      8.3.4.2.4. By End User
  8.3.5. Australia Clinical Trial Supplies Market Outlook
    8.3.5.1. Market Size & Forecast
      8.3.5.1.1. By Value
    8.3.5.2. Market Share & Forecast
      8.3.5.2.1. By Clinical Phase
      8.3.5.2.2. By Product & Services
      8.3.5.2.3. By Therapeutic Use
      8.3.5.2.4. By End User

9. MIDDLE EAST & AFRICA CLINICAL TRIAL SUPPLIES MARKET OUTLOOK

9.1. Market Size & Forecast
  9.1.1. By Value
9.2. Market Share & Forecast
  9.2.1. By Clinical Phase
  9.2.2. By Product & Services
  9.2.3. By Therapeutic Use
  9.2.4. By End User
  9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
  9.3.1. Saudi Arabia Clinical Trial Supplies Market Outlook
    9.3.1.1. Market Size & Forecast
      9.3.1.1.1. By Value
    9.3.1.2. Market Share & Forecast
      9.3.1.2.1. By Clinical Phase
      9.3.1.2.2. By Product & Services
      9.3.1.2.3. By Therapeutic Use
      9.3.1.2.4. By End User
  9.3.2. UAE Clinical Trial Supplies Market Outlook
    9.3.2.1. Market Size & Forecast
      9.3.2.1.1. By Value
    9.3.2.2. Market Share & Forecast
      9.3.2.2.1. By Clinical Phase
      9.3.2.2.2. By Product & Services
      9.3.2.2.3. By Therapeutic Use
      9.3.2.2.4. By End User
  9.3.3. South Africa Clinical Trial Supplies Market Outlook
    9.3.3.1. Market Size & Forecast
      9.3.3.1.1. By Value
    9.3.3.2. Market Share & Forecast
      9.3.3.2.1. By Clinical Phase
      9.3.3.2.2. By Product & Services
      9.3.3.2.3. By Therapeutic Use
      9.3.3.2.4. By End User

10. SOUTH AMERICA CLINICAL TRIAL SUPPLIES MARKET OUTLOOK

10.1. Market Size & Forecast
  10.1.1. By Value
10.2. Market Share & Forecast
  10.2.1. By Clinical Phase
  10.2.2. By Product & Services
  10.2.3. By Therapeutic Use
  10.2.4. By End User
  10.2.5. By Country
10.3. South America: Country Analysis
  10.3.1. Brazil Clinical Trial Supplies Market Outlook
    10.3.1.1. Market Size & Forecast
      10.3.1.1.1. By Value
    10.3.1.2. Market Share & Forecast
      10.3.1.2.1. By Clinical Phase
      10.3.1.2.2. By Product & Services
      10.3.1.2.3. By Therapeutic Use
      10.3.1.2.4. By End User
  10.3.2. Colombia Clinical Trial Supplies Market Outlook
    10.3.2.1. Market Size & Forecast
      10.3.2.1.1. By Value
    10.3.2.2. Market Share & Forecast
      10.3.2.2.1. By Clinical Phase
      10.3.2.2.2. By Product & Services
      10.3.2.2.3. By Therapeutic Use
      10.3.2.2.4. By End User
  10.3.3. Argentina Clinical Trial Supplies Market Outlook
    10.3.3.1. Market Size & Forecast
      10.3.3.1.1. By Value
    10.3.3.2. Market Share & Forecast
      10.3.3.2.1. By Clinical Phase
      10.3.3.2.2. By Product & Services
      10.3.3.2.3. By Therapeutic Use
      10.3.3.2.4. By End User

11. MARKET DYNAMICS

11.1. Drivers
11.2. Challenges

12. MARKET TRENDS & DEVELOPMENTS

12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments

13. GLOBAL CLINICAL TRIAL SUPPLIES MARKET: SWOT ANALYSIS

14. PORTER'S FIVE FORCES ANALYSIS

14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products

15. COMPETITIVE LANDSCAPE

15.1. Thermo Fisher Scientific Inc.
  15.1.1. Business Overview
  15.1.2. Products & Services
  15.1.3. Recent Developments
  15.1.4. Key Personnel
  15.1.5. SWOT Analysis
15.2. Almac Group
15.3. Novo Holdings A/S
15.4. Marken LLP
15.5. PCI Pharma Services
15.6. Sharp Services LLC
15.7. Cencora, Inc.
15.8. Myonex LLC
15.9. Parexel International Corporation
15.10. ICON Plc

16. STRATEGIC RECOMMENDATIONS

17. ABOUT US & DISCLAIMER